Department of Thoracic Surgery, NHO Yamaguchi-Ube Medical Center, 685 Higashi-kiwa, Ube, 755-0241, Japan.
Lung Cancer. 2012 Jan;75(1):95-101. doi: 10.1016/j.lungcan.2011.06.002. Epub 2011 Jun 29.
Expression of the transcription factor FOXP3 characterizes regulatory T cells (Tregs) that engage in the maintenance of immunological self-tolerance and immune homeostasis. Intra-tumoral accumulation of Tregs is associated with unfavorable prognosis in several kinds of cancers. Recently, expression of FOXP3 and its association with prognosis have also been shown in some cancer cells in clinical studies. For non-small cell lung cancer (NSCLC), however, prognostic significance of tumor FOXP3 expression and its relationship with Tregs remain unknown. FOXP3 expression in cancer cells and tumor-infiltrating lymphocytes was examined by immunohistochemical staining of surgical specimens from 87 patients with NSCLC. Prognostic values of the tumor-infiltrating Treg count and tumor FOXP3 expression status were evaluated retrospectively. FOXP3-positive cancer cells were observed in 27 of 87 (31.0%) patients. There was no significant relationship between Treg count and tumor FOXP3 status. Increased Treg counts were associated with worse overall and relapse-free survival whereas the influence of tumor FOXP3 status on survival was not significant. However, when FOXP3-positive cancer cells were present, the relationship between Treg accumulation and worse prognosis was attenuated. In contrast, patients without tumor FOXP3 expression and high Treg count had significantly worse overall and relapse-free survival (hazard ratio: 3.118 and 3.325, p=0.028 and 0.024, respectively) than other groups. These results suggest that tumor FOXP3 expression has a better prognostic potential in NSCLC and that in combination with tumor-infiltrating Treg count the absence of tumor FOXP3 allows the selection of high-risk patients.
转录因子 FOXP3 的表达特征在于调节性 T 细胞(Tregs),其参与维持免疫自身耐受和免疫稳态。在几种癌症中,Tregs 的肿瘤内积累与不良预后相关。最近,在一些癌症细胞的临床研究中也显示了 FOXP3 的表达及其与预后的关系。然而,对于非小细胞肺癌(NSCLC),肿瘤 FOXP3 表达的预后意义及其与 Tregs 的关系尚不清楚。通过对 87 例 NSCLC 手术标本的免疫组织化学染色,检查了癌细胞和肿瘤浸润淋巴细胞中的 FOXP3 表达。回顾性评估了肿瘤浸润性 Treg 计数和肿瘤 FOXP3 表达状态的预后价值。在 87 例患者中有 27 例(31.0%)观察到 FOXP3 阳性癌细胞。Treg 计数与肿瘤 FOXP3 状态之间没有显著关系。增加的 Treg 计数与总生存期和无复发生存期较差相关,而肿瘤 FOXP3 状态对生存的影响并不显著。然而,当存在 FOXP3 阳性癌细胞时,Treg 积累与较差预后之间的关系减弱。相比之下,没有肿瘤 FOXP3 表达和高 Treg 计数的患者总生存期和无复发生存期明显更差(危险比:3.118 和 3.325,p=0.028 和 0.024),明显差于其他组。这些结果表明,肿瘤 FOXP3 表达在 NSCLC 中具有更好的预后潜力,并且与肿瘤浸润性 Treg 计数相结合,肿瘤 FOXP3 缺失允许选择高危患者。